RSS Feeds
Search

Press releases

Press releases

Displaying 1..10 of 226 - per page Next page
Order by
ReGen Therapeutics Plc ('ReGen' or 'the Company') is developing an important new use for zolpidem, a long-established and safe treatment for insomnia. More
Technology Catalysts International has identified oral thin films as a breakthrough technology that accelerates pharmaceutical product market introductions. More
New report series from Decision Resources allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data More
A technology, developed by researchers at NUI Galway's National Diagnostics Centre supported by Enterprise Ireland and Innogenetics, is now the basis for tests that diagnose bacterial and fungal infections in blood. More
Labtec´s licensee ratiopharm started marketing in Canada a transdermal patch containing fentanyl for treatment of strong chronic pain, which is generic to J&J´s blockbuster Durogesic®. More
Product differentiation will be essential for drugs to compete in the market, according to a new report from Decision Resources More
GRUPO URIACH and a group of four financial investors - INVERCARTERA (GRUPO CAIXA CATALUNYA), CAJA DUERO, HARMISH & MYTAROS and NAJETI CAPITAL - have closed an agreement by which the latter acquire a minority stake in URIACH's subsidiary PALAU PHARMA More
Established therapies will lose significant share, according to a new report from Decision Resources More
Extent of market penetration by premium-priced biologics will hinge on scrutiny of third-party payers, according to a new report from Decision Resources More
GenOdyssee S.A. announced today that the Journal of antimicrobial Agents and Chemotherapy (AAC*), has accepted a manuscript describing stronger and more sustained inhibitory effect of GenOdyssee's lead antiviral drug candidate, GEA007.1 More
Displaying 1..10 of 226 - per page Next page
Order by

Related Reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us